9 Einträge |
Seite 1 / 1
![]() |
Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. |
Werzowa J, Koehrer S, Strommer S, Cejka D, Fuereder T, Zebedin E, Wacheck V |
The Journal of investigative dermatology. 2010 Nov 4. pii: jid2010327. doi: 10.1038/jid.2010.327 |
PMID: 21048785 |
Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance. |
Simma O, Zebedin E, Neugebauer N, Schellack C, Pilz A, Chang-Rodriguez S, Lingnau K, Weisz E, Putz EM, Pickl WF, Felzmann T, Müller M, Decker T, Sexl V, Stoiber D |
Cancer research. 2009 Jan 1. pii: 69/1/203. doi: 10.1158/0008-5472.CAN-08-1705 |
PMID: 19118004 |
Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. |
Zebedin E, Simma O, Schuster C, Putz EM, Fajmann S, Warsch W, Eckelhart E, Stoiber D, Weisz E, Schmid JA, Pickl WF, Baumgartner C, Valent P, Piekorz RP, Freissmuth M, Sexl V |
Blood. 2008 Aug 6. pii: blood-2008-02-139105. doi: 10.1182/blood-2008-02-139105 |
PMID: 18684865 |
Signal interception-based therapies--a double-edged sword in Bcr/abl-induced malignancies? |
Zebedin E, Freissmuth M, Sexl V |
Leukemia & lymphoma. 2008 Apr 9. pii: 792012467. doi: 10.1080/10428190701858872 |
PMID: 18398721 |
JunB is a gatekeeper for B-lymphoid leukemia. |
Ott RG, Simma O, Kollmann K, Weisz E, Zebedin EM, Schorpp-Kistner M, Heller G, Zöchbauer S, Wagner EF, Freissmuth M, Sexl V |
Oncogene. 2007 Feb 12. pii: 1210285. doi: 10.1038/sj.onc.1210285 |
PMID: 17297445 |
c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6. |
Kollmann K, Heller G, Ott RG, Scheicher R, Zebedin-Brandl E, Schneckenleithner C, Simma O, Warsch W, Eckelhart E, Hoelbl A, Bilban M, Zöchbauer-Müller S, Malumbres M, Sexl V |
Blood. 2011 Feb 7. pii: blood-2010-07-299644. doi: 10.1182/blood-2010-07-299644 |
PMID: 21300982 |
Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression . |
Schmetterer KG, Goldhahn K, Ziegler LS, Gerner MC, Schmidt RLJ, Themanns M, Zebedin-Brandl E, Trapin D, Leitner J, Pickl WF, Steinberger P, Schwarzinger I, Marculescu R |
Frontiers in immunology. 2019 Jul 30. doi: 10.3389/fimmu.2019.01790. pmc: PMC6682678 |
PMID: 31417563 |
Regimen-dependent synergism and antagonism of treprostinil and vildagliptin in hematopoietic cell transplantation. |
Zebedin-Brandl E, Themanns M, Kazemi Z, Nasrollahi-Shirazi S, Mussbacher M, Heyes E, Meissl K, Prchal-Murphy M, Strohmaier W, Krumpl G, Freissmuth M |
Journal of molecular medicine (Berlin, Germany). 2019 Dec 24. doi: 10.1007/s00109-019-01869-8. pii: 10.1007/s00109-019-01869-8 |
PMID: 31872285 |
Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria. |
Kossmeier M, Themanns M, Hatapoglu L, Kogler B, Keuerleber S, Lichtenecker J, Sauermann R, Bucsics A, Freissmuth M, Zebedin-Brandl E |
Frontiers in pharmacology. 2021 Aug 13. doi: 10.3389/fphar.2021.726758. pii: 726758. pmc: PMC8414520 |
PMID: 34483937 |
9 Einträge |
Seite 1 / 1
![]() |